Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Ocrevus Market Forecast Highlighting Growth From $ Billion To $ Billion
The expansion seen in earlier years was driven by a deeper comprehension of multiple sclerosis disease mechanisms, regulatory approvals for therapies that modify the disease’s course, a broader network of specialized neurology services, a higher frequency of MS diagnoses, and the establishment of facilities capable of administering biologic infusions.
The forecast period’s expansion is driven by a growing preference for individualized multiple sclerosis therapies, an increase in home-based and outpatient infusion options, heightened funding for neuroimmunology studies, greater emphasis on decelerating disease advancement, and the creation of advanced monoclonal antibodies. Key developments shaping this period include the heightened application of monoclonal antibody treatments for MS, a surge in the use of B-cell-focused medications, broader implementation of infusion center care systems, an increased priority on achieving sustained disease modification, and improved patient oversight along with the gathering of real-world data.
Download A Free Sample Report For Comprehensive Market Insights:
Ocrevus Market Growth Drivers: What Factors Are Accelerating Expansion?
The growing prevalence of multiple sclerosis is anticipated to fuel the expansion of the Ocrevus market in the coming period. Multiple sclerosis (MS) represents a chronic autoimmune condition that impacts the central nervous system, wherein the immune system erroneously attacks the protective myelin sheath surrounding nerve fibers. This increase in MS cases stems from a blend of genetic, environmental, and lifestyle influences, such as enhanced diagnostic methods, heightened public awareness, and shifts in dietary patterns and urban lifestyles. Ocrevus functions to manage MS by lessening disease activity, decelerating progression, and alleviating symptoms through the targeted depletion of CD20-positive B-cells, which are involved in the immune-mediated harm seen in MS. As an example, in May 2024, the MS Society UK, a non-profit organization based in the United Kingdom, reported that over 150,000 individuals are living with MS in the UK as of 2024, with prevalence rising by 15% in England, 10% in Scotland, 9% in Northern Ireland, and 8% in Wales. Consequently, the increase in multiple sclerosis cases will propel the Ocrevus market forward.
Ocrevus Market Driver: Growing Focus On Personalized Medicine Driving Ocrevus Market Expansion
The expanding emphasis on personalized medicine is set to drive the growth of the Ocrevus market in the future. Personalized medicine assists healthcare professionals in designing customized treatment regimens and making well-informed therapeutic decisions by leveraging a patient’s genetic profile to comprehend their condition. This focus on personalized medicine is gaining traction because of its ability to boost treatment efficacy, minimize side effects, and meet the rising need for individualized healthcare solutions, fueled by progress in genetic and diagnostic technologies. This trend positively influences Ocrevus by facilitating its targeted therapy for multiple sclerosis, which enhances patient results and cements its status as a favored treatment option. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, noted that in 2023, the FDA sanctioned 16 new personalized therapies for patients with rare diseases, a substantial jump from the six approved in 2022. Hence, the growing adoption of personalized medicine is expected to propel the Ocrevus market’s expansion.
Ocrevus Market Segmentation: How Is The Market Structured Across Key Categories?
The ocrevus market covered in this report is segmented –
1) By Clinical Indications: Relapsing-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis
2) By Formulation: Liquid Formulations, Tablet Or Capsule Formulation
3) By Route Of Administration: Oral, Injectable
4) By End User: Hospitals, Retail Pharmacies, Online Pharmacies
Ocrevus Market Trends: What Is Shaping Future Industry Growth?
Key industry players within the Ocrevus landscape are directing their efforts toward creating innovative products, particularly subcutaneous combination formulations, in response to the growing need for easier administration, enhanced treatment adaptability, and expanded accessibility for multiple sclerosis patients. These subcutaneous formulations integrate therapeutic monoclonal antibodies with agents that boost absorption, enabling faster delivery and a lighter infusion burden compared to conventional intravenous approaches, which demand extended administration durations in medical facilities. For example, in September 2024, Genentech Inc., a biotechnology firm based in the United States, disclosed that the U.S. Food and Drug Administration (U.S. FDA) had approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the management of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo stands as the first and only subcutaneous (SC) injection that can be given by healthcare providers twice a year, with each session lasting roughly 10 minutes. This landmark approval offers individuals affected by multiple sclerosis (MS) an increased number of therapeutic choices and grants healthcare professionals more flexibility to customize care according to the distinct requirements of every patient.
Ocrevus Market Competitive Landscape And Leading Companies
Major companies operating in the ocrevus market are F. Hoffmann-La Roche Ltd.
Access The Complete Ocrevus Market Report:
Ocrevus Market Largest Region By Revenue And Market Share
North America was the largest region in the ocrevus market in 2025. The regions covered in the ocrevus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model